What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
Guardado en:
Autor principal: | Nicola Silvestris |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9818b25054714dda8dc3970dda1d96f3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
por: Shai Efrati, et al.
Publicado: (2021) -
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
por: Yamato Nishiguchi, et al.
Publicado: (2021) -
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
por: Peter Bergman, MD, et al.
Publicado: (2021) -
Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
por: Serge Goldman, et al.
Publicado: (2021) -
Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Rana Shibli, et al.
Publicado: (2021)